Entrada Therapeutics, Inc.

NASDAQ:TRDA

Biotechnology

Healthcare
$5.03 +0.37%

+$0.03 today

Market cap
$196.93M
Beta
-0.26
P/E (TTM)
-1.7
EPS (TTM)
-$3.97
52W Low $4.93High $16.45

Volume 0.82M

Average 0.36M

TRDA Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Entrada Therapeutics, Inc.NASDAQ: TRDA

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin dips below year-ago levels

Q1 FY2026 selling, general & admin of $10.12M fell 1.5% year over year, behind the +4.0% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 6.0% from the prior quarter. Over 3 fiscal years it compounded at +10.2% a year.

Context

  • Selling, general & admin amounted to 161.5% of revenue in FY2025, up 143.2 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 4 analysts of $3.27M (-92.0%) for the fiscal year ending Dec 2026, a slowdown from the +6.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$10.12M+6.0% QoQ
Last fiscal yearDec 2025
$41.05M+6.7% YoY
LTMMar 2026
$40.9M+4.0% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.5%-83.4%-82.0 pp
1 year+6.7%-92.0%-98.7 pp
3-year CAGR+10.2%-29.8%-40.0 pp
5-year CAGR+20.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
41.05M USD
Year-over-year change
+6.7%
4-year CAGR
+28.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How TRDA compares with its peers on the latest reported figures

  • TRDA's LTM Mar 2026 selling, general & admin of $40.9M is the 5th highest of the 11 companies compared; the peer median is $34.68M.
  • Its year-over-year change of +4.0% is the 6th highest of 11, against a peer median of +1.9%.
  • Selling, general & admin amounts to 712.8% of revenue for TRDA, versus a peer median of 108.4%.
TRDA Competitors Peer median
Selling, General & Admin for TRDA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMRXImmuneering CorporationLTM Mar 2026$4.7B +29505.3%+3.5%—
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$256.23M +54.0%+20.4%117.7%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$55.88M -11.2%-10.5%—
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$43.57M -11.6%+0.0%96.1%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$40.9M +4.0%+10.2%712.8%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$36.17M -2.1%+6.6%99.1%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$33.2M +76.0%+43.8%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$30.28M -34.0%-12.3%—
HUMAHumacyte, Inc.LTM Mar 2026$27.31M -10.2%+10.9%1354.8%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$26.76M +58.7%+29.7%—
SGMTSagimet Biosciences Inc.LTM Mar 2026$18.03M +5.9%+42.7%—
Peer median (excluding TRDA) $34.68M+1.9%+8.7%108.4%

Competitors are the stored peer set for TRDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00129.01M210.78M25.42M
Cost of Revenue00004.1M
Gross Profit00129.01M210.78M21.33M
Gross Margin——100.0%100.0%83.9%
Research & Development35.93M66.61M99.88M125.31M142.27M
Selling, General & Admin15.2M30.64M32.29M38.47M41.05M
Operating Expenses51.13M97.25M132.18M163.77M177.32M
Depreciation & Amortization1.12M1.9M2.84M3.77M425K
EBITDA(50.04M)(90.09M)14.9M70.26M(142.4M)
EBITDA Margin——11.5%33.3%-560.2%
Operating Income(51.13M)(97.25M)(3.16M)47.01M(156M)
Operating Margin——-2.5%22.3%-613.7%
Interest Income02.63M15.22M19.47M0
Interest Expense02.63M000
Other Income / Expenses(31K)2.63M15.22M19.47M13.17M
Income Before Tax(51.16M)(94.62M)12.06M66.49M(142.83M)
Pre-Tax Margin——9.3%31.5%-561.8%
Income Tax Expense0018.74M859K924K
Net Income(51.16M)(94.62M)(6.69M)65.63M(143.75M)
Net Margin——-5.2%31.1%-565.5%
EPS (Basic)(1.60)(2.79)(0.20)1.76(3.47)
EPS (Diluted)(1.60)(2.79)(0.20)1.68(3.47)
Weighted Avg Shares31.22M31.29M33.05M37.31M41.37M
Weighted Avg Shares (Diluted)31.22M31.29M33.05M39M41.37M

Entrada Therapeutics, Inc.

NASDAQ:TRDA

Intrinsic Alpha fair value

Locked

Current Price

$5.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.